Background: Cancer treatment in the 21st century has seen immense advances in opti-
1 | INTRODUCTION
| Skin cancer
Skin cancer occurs as two main types, ie, non-melanoma and melanoma. Non-melanoma types include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which are of keratinocyte origin, as well as Merkel cell carcinoma (MCC), sebaceous gland tumors, and malignant pilomatrixoma. 1, 2 Melanoma types include superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nodular melanoma (NM), acral lentiginous melanoma (ALM), mucosal melanoma, desmoplastic melanoma, and nevoid melanoma. 3 In addition, non-melanoma skin cancers (NMSC) can have more than one histological subtype, in which case they are referred to as mixed types. 4 There is variability in the behavior of different types of skin cancer, as well as histopathological variants, depending on growth patterns. 4 For example, BCC carcinomas grow slowly, with damage to surrounding tissue, but rarely spreads to vital structures, whereas SCC and melanomas are aggressive and are more likely to metastasize. 5, 6 Solar and actinic keratitis, viral warts, and Bowen disease increase the risk of NMSC, while clinically atypical mole (CAM), giant congenital melanocytic nevi, and lentigo maligna have been
shown to increase the risk of developing melanoma. 7 The risk of developing skin cancer is also higher in people with poor immune function (such as HIV/AIDS and solid organ transplant patients) [8] [9] [10] and people of fair skin color. [10] [11] [12] [13] [14] The observed increases in skin cancer rates are associated with several factors, including the fact that older populations are at higher risk of NMSC, and also increased occupational and recreational UV light exposure 15, 16 ( Figure 1 ). For instance, studies have shown that indoor tanning is associated with a significantly increased risk of BCC and SCC, with a higher risk with use in early life (<25 y). 17 Each year in the United States, over 5.4 million cases of NMSC are treated in more than 3.3 million people. 18 In 2017, it was estimated that 87 110 new cases of invasive melanoma were diagnosed in the United
States and an estimated 9730 people were casualties of this aggressive type of skin cancer. 19 The annual cost of treating skin cancers in the United States is estimated at $8.1 billion: about $4.8 billion for NMSC and $3.3 billion for melanoma. 20 
| Current skin cancer treatment
The use of conventional cancer therapies for skin cancers has been fraught with poor specificity in targeting the cancer cells, partly due to variations in surface receptor expressed by tumor cells. 21 Surgical therapy may be used depending on the type and location of cancer, age of person, and whether the cancer is in the primary or recurring stages. 22 For example, a person (<50 y of age), diagnosed with BCC, can undergo a surgical excision known as Mohs surgery. Mohs micrographic surgery removes skin cancer one layer at a time, each time examining these layers under a microscope immediately after removal.
Although this procedure allows for minimal scarring by preserving healthy tissue, it is time consuming (3-4 h to remove a single lesion) and expensive. [23] [24] [25] Superficial removal of cancerous tissue can be done with cautery and curettage using a spoon-like instrument with a sharp edge. 26 Another surgical procedure that may be used for skin cancer is electrosurgery, which is a procedure that cuts/destroys/cauterizes tissue using a high-frequency electric current applied locally with a pencil-shaped metal instrument.
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For low-risk disease or treatment of elderly patients, radiation therapy (external beam radiotherapy or brachytherapy), 28 topical chemotherapy (5-fluorouracil), 29 and cryotherapy (freezing the cancer off) 30 can provide adequate control of the disease. However, the topical application of 5-fluorouracil often fails due to the inadequate frequency and/or length of treatment, insufficient drug concentration, and a poor penetration of the cream into the epidermis, which contributes to tumor recurrence. 29 Hence, personalized/precision medicine has emerged because of its potential to improve the accuracy of tumor targeting and minimize toxicity to normal tissue. The beneficial role of novel-targeted therapies and the potential use of SNAP-tag fusion FIGURE 1 A sketch showing the squamous cells, melanocytes, and basal cells found in the epidermal layer of the skin. Ultraviolet (UV) light from the sun can damage the DNA in these skin cells and give rise to SCC, BCC, or melanoma proteins in cutaneous cancers is described hereafter. This review seeks to elaborate more on the applications of these diagnostic and therapeutic treatment modalities.
| Targeted drug and molecular therapies in skin cancers
The field of cancer immunotherapy attempts to target and kill cancer cells by manipulating the body's immune system and has been immensely successful for the treatment of skin cancer. 31 (Table 1) . DTIC is more commonly used as the current standard treatment for metastatic melanoma. [32] [33] [34] Until recently, single-agent chemotherapy using DTIC has produced the best therapeutic outcome, with 5% to 15% of patients responding to the therapy, although less than 2% survive 6 years post treatment. 33, 37 Since the discovery of the BRAF V600E mutation in melanomas, three BRAF inhibitors-vemurafenib, trametinib, and dabrafenib-have been used to stop signals that cause cancer cells to grow and divide. However, these drugs are associated with serious side effects, as highlighted in Table 1 . 38, 39 As persistent inflammation has emerged as a cardinal hallmark of cancer, 40 targeting toll-like receptors (TLRs) is also hypothesized as a plausible potential molecular approach for skin cancer therapies. 41 Another successful treatment option in patients with melanoma is the use of monoclonal antibodies (mAbs), which are immune checkpoint inhibitors. For example, the monoclonal antibody ipilimumab is directed toward the cytotoxic T-lymphocyte antigen (CTLA)-4 and was the first (CTLA)-4 inhibitor to demonstrate an improved overall survival rate in melanoma patients. 42 Other mAbs such as nivolumab bind to the programmed-cell death (PD)-1 receptor and block interaction with PD-L1 and PD-L2 ligands. 43 This binding releases PD-1 pathway-mediated immune responses against tumor cells. 43 Recently, anti-programmed cell death-1 (Anti-PD-1) was approved for the treatment of patients with advanced melanoma. 37 Although PD1 blockers have comparatively better safety, the main concern with PD1 monotherapy is patient response rate (around 30%-40%). 44 The pegylated version of interferon α-2b (PEG-IFN) has been approved as an adjuvant for surgically resected "high-risk" melanoma patients. 45 However, these mAbs are associated with severe side recognized as "foreign" and therefore induce a host immune response.
This can result in reduced efficacy of the mAb, due to increased clearance. 52, 53 This results in rapid and tight binding to the outer surface of a tumor and reduced numbers of antibodies diffusing to the core of the tumor.
This is because rate of diffusion is approximately inversely proportional to the cube root of molecular weight. 60, 61 Thus, the intended effects of the mAb would not be universal to all tumor cells. 60, 62 Many nanoparticle-based drug delivery systems have been approved by the FDA and are currently undergoing clinical trials for skin cancer therapy. 63 It has been shown that delivering the chemotherapeutic agent doxorubicin by gold nanoparticles was very effective against a melanoma cell line. 64 Lo Prete et al applied a cholesterol-rich nanoemulsion to deliver etoposide in a mouse model of melanoma. 65 The nanoemulsion delivery was associated with decreased side effects, increasing maximum tolerated dose fivefold and increased inhibition of tumor growth by concentrating etoposide at the tumor site (a fourfold higher concentration in tumor than with free etoposide). 65 Nonetheless, nanoparticles as efficient drug delivery systems are hindered by incomplete toxicological assessment, low drug-loading capacities, difficulty in scale-up production, and low stability. 66 Natural compounds have been suggested for use alone 67, 68 or in combination with photodynamic therapy (PDT) 69 in the treatment of skin cancer. PDT is a treatment modality that uses an effector molecule called a photosensitizer (PS), followed by local illumination with visible light of specific wavelength(s). When a PS is exposed to a specific wavelength of light, it produces reactive oxygen species (ROS) that induce apoptosis of cancerous lesions. 70 To date, targeting cancer cells using PDT has relied on the passive accumulation of PS in tumor tissues, which might not lead to optimal dosage of PS, thus leading to the application of relatively high dosage of PS within the tumor. 71 As a result, PDT may damage healthy tissues, by causing prolonged skin photosensitivity. 72 Efforts to bypass this lack of specificity have focused on the identification of specific cancer biomarkers, drug conjugates, and resistant mechanisms contributing to cancer survival after therapeutic treatments.
The addition of SNAP-tag technology to skin cancer management potentially presents a more structurally reliable method for conjugation and delivery of photosensitizer or cytotoxic payload for targeted cancer chemotherapeutic purposes, as discussed below. complementary scFvs produced as a single chain called tandem scFvs. 77 The small size of the scFv (27 kDa) allows for better clearance from the body, better tissue/tumor penetration, and simple and straightforward production in bacterial cell systems vs mammalian cells. 74, 76, 80 The construct also produces a high tumor to background ratio with high visualization and a low nonspecific background signal. [81] [82] [83] [84] By identifying tumor-specific antigens (TAAs) for melanoma, BCC, or SCC and targeting them with an advanced recombinant SNAP-tag antibody-labeling technology, tumors can be screened prior to therapy and the appropriate treatment modality implemented. 85 One such treatment modality that shows promising potential with the use of SNAP-tag technology is photoimmunotherapy (PIT).
| Targeted drug conjugation and SNAP-tag technology
A SNAP fusion protein is a type of ADC that exhibits similarities and differences to conventional ADCs. The following similarities between the both are clear from profiles, off-target side effects and a relatively low maximum tolerated dose. 86 The type of linker (cleavable or noncleavable) also impacts on the efficacy of the ADC. For example, these linkers facilitate premature spontaneous drug release, which damages normal tissues. 87 SNAP-tag is genetically fused to the scFv and conjugated to the cytotoxic agent via an autocatalytically generated covalent bond through the cysteine residue of the enzymes catalytic site with the benzylguanine-modified agent to generate a homogenous construct with a higher therapeutic index. 73, 75 This creates a single specific site for conjugation and allows an optimal 1:1 stoichiometry, which does not affect the activity of the recombinant ligand and overcomes the antigenic materials for the immune system to respond to. Continued therapy with imiquimod after laser therapy ensured that the devitalized tumor was engulfed and processed by recruited dendritic cells. 92 In 2010, another in situ PIT study was performed on patients with metastatic melanoma. 93 The components of PIT included the local application of imiquimod irradiated with laser light. Eleven patients received this treatment modality in one or multiple 6-week treatment cycles, and a 12-month overall survival rate of 70% with no toxic side effects was observed. 93 In 2017, Naylor et al used a novel immunological approach for treatment of metastatic cancers, called laser immunotherapy, in combination with the check point inhibitor ipilimumab, to treat melanoma. 94 It was observed that after laser immunotherapy on one patient, cutaneous melanoma in the head and neck completely disappeared. 94 The patient was then administered one course of ipilimumab, 3 months after laser treatment, and all tumor nodules in the lung decreased. The patient remained tumor free for 1 year. 94 This highlights the efficacy of combination treatment in enhancing therapeutic effects in melanoma treatment.
Another newly developed cell-selective cancer therapy is nearinfrared photoimmunotherapy (NIR-PIT). Its promising potential in skin therapy is attributed to reduced photon scattering, light absorption, and auto-fluorescence, as well as increased light penetration into tissue, as compared with PDT. 95 NIR-PIT can target a broad array of cancer-specific target molecules including the proteins EGFR, HER2, PSMA, CD25, CEA, mesothelin, GPC3, and CD20. 96 Since NIR-PIT can selectively kill off target cells, it can be used to eliminate cancer stem cells displaying markers such as CD44 and CD133, as was demonstrated for breast cancer and glioblastoma stem cells. 96 This creates the possibility of using this option to target antigens associated with melanoma or BCC.
EpCAM (CD 326) is a human transmembrane glycoprotein located on the cell membrane and within the cytoplasm of all non-squamous epithelial cells. 97 Previous studies have shown that anti-EpCAM antibody Ber-EP4 is a sensitive marker of basal cell carcinoma; however, it fails to stain cutaneous squamous cell carcinoma. 98, 99 Chondroitin sulfate proteoglycan 4 (CSPG4), also known as melanoma chondroitin sulfate proteoglycan (MCSP), is a membrane-bound proteoglycan and was initially characterized on the surface of melanoma cells.
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Targeting CSPG4 was also shown to be clinically relevant by an increase in survival of melanoma patients who received CSPG4 mimics as a form of active specific immunotherapy. 102 Targeting CSPG4 also inhibited the growth and recurrence of melanoma in a human melanoma xenograft model. 103 Two photosensitizers (PS) that are currently used in NIR-PIT are IR700 and hypericin. IR700 is a promising PS that, besides having no off-target effects, possesses ideal properties such as high purity, photostability, and a strong absorption peak close to 700 nm allowing improved light penetration into tissues. 90, [104] [105] [106] [107] Recently, the IR700 fluorophore was conjugated to a scFv fragment against three overexpressed cancer antigens, ie, the EGFR, EpCAM, and CSPG4, using SNAP-tag technology. 76, 88 In vitro success of this therapeutic approach in killing melanoma cells was attributed to the scFv-425
(EGFR) targeted effect, as well as the nontoxic effect of free IR700 even after irradiation. Recently, an attempt to circumvent chemoresistance was made by
Biteghe and Davids, who by combining DTIC with hypericin were able to overcome this resistance due to the genotoxic effect by DTIC and the oxidative stress induced by HYP-PDT. 116 Optical imaging methods have also seen widespread application in skin cancer diagnostics as they are noninvasive, with fast response times, and are potentially sensitive to biochemical and structural changes presented in skin cancer development.
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| Optical imaging methods in cancer diagnosis
For skin cancer diagnostics, the primary optical imaging techniques used are widefield imaging, optical spectroscopy, and microscopy imaging. 119 Widefield imaging allows the examination of large areas and has the potential of improving detection of hidden lesions, margin delimitation, and also guide biopsy site determination. 120 A major advantage of the widefield microscope is the low cost, simplicity, and flexibility of the system. 121 In contrast, some disadvantages of widefield microscopy include low image resolution, potential for shading artifacts due to uneven illumination, and the alignment of different cameras to ensure pixel registration when using multiple indicators.
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Microscopy imaging has the main advantage of the evaluation of the tissue characteristics at cellular level, but only a small fraction of the lesion volume is interrogated. 123 Optical spectroscopy presents more detailed information on tissue composition than widefield microscopy, as the light intensity for each collected emission wavelength is correlated to specific biomolecules. 124 Raman spectroscopy has gained considerable interest in disease diagnosis, particularly cancer, because of its ability to provide molecular specific information about tissues. Each
Raman spectral peak can be associated with specific vibrations in molecular bonds. 125, 126 In a study by Gong et al, an NIR fluorescent SNAP-tag substrate BG-800 was synthesized by conjugating an IRDye 800CW to the benzyl-guanine amino group (BG-NH 2 ) of the protein tag. 84 Because BG-800 was cell impermeable, the SNAP f -ADRβ2 fusion protein was used in such a way that ADRβ2 directed the localization of SNAP f fusion protein to the cell membrane. BG-800 reacted with SNAP f -ADRβ2 in both cell lysate and live cell culture. 84 The tumor expressing The EGFR-specific scFv fusion protein 425-SNAP was labeled with the NIR dye BG-747, and its accumulation, specificity, and kinetics were monitored using NIR fluorescence imaging in a subcutaneous pancreatic carcinoma xenograft model. 74 The 425 (scFv) SNAP fusion protein accumulated rapidly and specifically at the tumor site. Its small size allowed efficient renal clearance and a high tumor to background ratio (TBR).
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The SNAP-tag can also be combined with other protein tags, such as HaloTag, 134 or other reporter gene systems that use fluorescent substrates, such as β-galactosidase/DDAOG system, 135 to create multiplexed imaging systems. A second version of AGT-based tag named CLIP-tag reacts specifically with benzylcytosine (BC) derivatives. 136 Because SNAP-tag and CLIP-tag only react with their specific substrates, they could be used simultaneously for dual-color fluorescence imaging. 137 For example, the nonspecific blood flow tracer indocyanine green (ICG) was successfully used to visualize regional lymphatic flow from cancer lesions and identified sentinel lymph nodes in humans. 137 Simultaneous but separate visualization of different lymphatic drainages was made possible by fluorescent agents with multiple colors. 137 The clinical use of NIR fluorescence imaging for sentinel lymphatic mapping was first reported by Kitai et al in 18 breast cancer patients. 138 They injected 25 mg of ICG near the areola of breast cancer patients and successfully visualized the draining lymphatics in all patients and localized the sentinel lymph nodes in 17 of 18 patients. 138 Following this study, additional clinical studies have confirmed the utility of NIR sentinel mapping in melanoma. 139 Tumor detection with NIR fluorescence during a surgical procedure has been performed in several tumor types, with application in melanoma using ICG. 140 The subsequent conjugation of ICG to SNAP-tag thus creates new possibilities for image guided surgery in melanoma patients in the future.
As shown in Figure 4A , the scFv targets the fusion protein to the surface receptor on the tumor, cell and the conjugated photosensitizer (IR 700) is activated by a specific wavelength of light (500-700 nm). The energy-enriched photosensitizer releases the extra energy to its surroundings and returns to the ground state.
Singlet O 2 is converted to reactive oxygen species (ROS), which induces apoptosis/necrosis of tumor cells. 88 This application is referred to as photoimmunotherapy; in Figure 4B , auristatin F (AURIF) (microtubule destabilizer) conjugated to the SNAP-tag antibody fusion protein gets internalized and released into the cytosol where it induces apoptosis, 141 referred to as ADC therapy. In Figure 4 ; C & D, fluorophores and magnetofluorescent nanoparticles enter the cell by receptor-mediated uptake and used for optical imaging. 131, 142 After their release, their corresponding signals accumulate within the tumor and allow for optical detection. These are a few examples that prove the versatility of SNAP-tag technology, which depending on the type of the BG modified substrate conjugated will either elicit signal accumulation for diagnosis 88, 131, 142 or induce apoptosis to eliminate cancer cells.
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| CONCLUSION
In the era of precision medicine, SNAP-tag technology is a potentially promising molecular targeting approach for early diagnosis and treatment of skin cancer, which has a high burden globally. In this review, we have identified and discussed the prospects for the use of SNAP-tag for targeted therapy of skin cancers, as well as some of its potential advantages over currently available conventional skin cancer treatment options.
Not least, the use of SNAP-tag technology in combination with other recently emerging 'omics-based technologies can potentially offer a treasure trove of targeted diagnostic, prognostic, and therapeutic options for the management of skin cancers in a systems-oriented manner. 
